DOSTINEX TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

CABERGOLINE

Pieejams no:

PFIZER CANADA ULC

ATĶ kods:

G02CB03

SNN (starptautisko nepatentēto nosaukumu):

CABERGOLINE

Deva:

0.5MG

Zāļu forma:

TABLET

Kompozīcija:

CABERGOLINE 0.5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

8

Receptes veids:

Prescription

Ārstniecības joma:

ERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0141281001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2001-03-02

Produkta apraksts

PRODUCT MONOGRAPH
PR
DOSTINEX
®
(cabergoline)
Tablets 0.5 mg
Dopamine Receptor Agonist
Pfizer Canada Inc.
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
REVISION DATE:
23 JULY 2013
Dist. by: Paladin Labs Inc.
St-Laurent, Quebec H4P 2T4
CONTROL NO. 164062
®
Pharmacia & Upjohn S.P.A.
Pfizer Canada Inc., Licensee
© Pfizer Canada Inc. 2013
_ _
_DOSTINEX* (cabergoline) Product Monograph _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................16
STORAGE AND STABILITY
..........................................................................................18
SPECIAL HANDLING INSTRUCTIONS
.......................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL INFORMATION
.................................................................